Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Shorter TB treatment regimens should be safer as well
Oxana Rucsineanu, P. Agbassi, Rosa María Blanca Herrera, et al.
Public Health Action (2023) Vol. 13, Iss. 3, pp. 104-106
Open Access | Times Cited: 10

Showing 10 citing articles:

Equitable, personalised medicine for tuberculosis: treating patients, not diseases
Lorenzo Guglielmetti, Samiran Panda, Amanzhan Abubakirov, et al.
The Lancet Respiratory Medicine (2025)
Closed Access | Times Cited: 1
Fighting tuberculosis hand in hand: A call to engage communities affected by TB as essential partners in research
Nandini Venkatesan, Lena Faust, Roanna Lobo, et al.
PLOS Global Public Health (2025) Vol. 5, Iss. 4, pp. e0004437-e0004437
Open Access
Is shorter the solution for tuberculosis treatment?
Rosa María Blanca Herrera, Jennifer Furin
The Lancet Infectious Diseases (2025)
Closed Access
Research on the treatment of rifampin-susceptible tuberculosis—Time for a new approach
William J. Burman, Oxana Rucsineanu, C. Robert Horsburgh, et al.
PLoS Medicine (2024) Vol. 21, Iss. 7, pp. e1004438-e1004438
Open Access | Times Cited: 3
Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review
William J. Burman, Pauline Luczynski, C. Robert Horsburgh, et al.
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 1
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls
Theresa Ryckman, Nicole Salazar‐Austin
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 6, pp. 420-421
Closed Access
Economic aspects of shortening the duration of tuberculosis treatment
Malaisamy Muniyandi, Karikalan Nagarajan
The Lancet Global Health (2024) Vol. 12, Iss. 6, pp. e901-e902
Closed Access
Expanding evidence for shortened treatment of latent tuberculosis infection: progress, not perfection
Amy Beeson, Randall Reves, Robert Belknap
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 11, pp. 1339-1340
Closed Access
Assessing Hepatotoxicity in Novel and Standard Short Regimens for Rifampicin-Resistant Tuberculosis: Insights from the TB-TRUST and TB-TRUST -plus Trials
Lingyun Song, Yilin Zhang, Feng Sun, et al.
International Journal of Infectious Diseases (2024) Vol. 148, pp. 107230-107230
Open Access
Inappropriate use of Tuberculosis medications among TB patients in Vientiane capital, Lao People’s Democratic Republic
Chansouk Vongsansouvanh, Chitdavonh Her, Chanthanom Manythip, et al.
International Journal of Public Health Asia Pacific (IJPHAP) (2024), pp. 75-85
Closed Access
Current challenges and future development of India’s healthcare system’ towards tuberculosis free India – research evidence and programmatic initiatives
Gopalan Narendran, Ariarathinam Newtonraj, Luke Elizabeth Hanna, et al.
(2024) Vol. 1, Iss. 1, pp. 35-58
Closed Access
Page 1

Scroll to top